Here's Why You Should Hold Cencora Stock in Your Portfolio for Now
Cencora COR is well-poised for growth on the back of a robust U.S. Healthcare Solutions business and product launches. However, intense competition is a concern.
This Zacks Rank #3 (Hold) company’s shares have gained 18.9% in the past six months compared to the industry’s 0.4% growth. The S&P 500 Index has gained 1.8% in the same time frame.
Cencora is one of the world’s largest pharmaceutical service companies. It is focused on providing drug distribution and related services to reduce healthcare costs and improve patient outcomes. The company has a market capitalization of $67.28 billion.
Image Source: Zacks Investment Research
COR’s bottom line is anticipated to improve 12.2% over the next five years. Its earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 3.93%.
Let’s delve deeper.
MSO Strategy Strengthening Vertical Integration and Margin Profile: Cencora’s expansion into pharmaceutical-centric MSOs, particularly through the OneOncology acquisition, enhances its vertical integration across the specialty value chain. MSOs provide high-margin revenue streams while deepening relationships with physicians and biopharma companies.
Management emphasized that the MSO model enables cross-platform synergies such as clinical research, revenue cycle management and data-driven insights. These businesses carry lower revenues but higher operating margins, supporting profitability expansion. This strategy structurally shifts CencoraCOR-- toward more differentiated, service-oriented revenue streams with stronger long-term earnings visibility.
Upward Revision in Guidance Reflects Strong Execution: Cencora raised its fiscal 2026 outlook, now expecting 7-9% revenue growth and 11.5–13.5% operating income growth, driven by continued strength in the U.S. segment and contributions from OneOncology.
U.S. Healthcare Solutions operating income growth guidance was notably increased to 14-16%, reflecting strong execution despite customer losses. This upgrade signals confidence in underlying demand trends, pricing resilience and operational efficiency. The ability to raise guidance early in the fiscal year suggests strong earnings drivers and reinforces management’s credibility in delivering consistent growth.
Resilience in Pricing Dynamics Despite Regulatory Pressures: Cencora demonstrated strong negotiating power with manufacturers, maintaining gross profit dollars despite list price reductions tied to regulatory changes. Management noted successful contract renegotiations that preserved economics even as pricing dynamics evolved. This reflects the company’s critical role in the pharmaceutical supply chain, where scale and logistics capabilities provide leverage. Additionally, the ability to offset pricing pressure with volume growth and contract structures highlights resilience in its business model, mitigating one of the key risks typically associated with drug distribution businesses.
Downsides
International Segment Profitability Volatility: Despite solid revenue growth, the International Healthcare Solutions segment reported a 14% decline in operating income, primarily due to timing-related pricing adjustments in certain markets.
While management expects normalization later in the year, this highlights the segment’s sensitivity to pricing cycles and regional dynamics. International markets often carry lower margins and higher regulatory complexity, which can create earnings volatility. Continued unpredictability in pricing adjustments or reimbursement timelines could constrain profitability despite top-line growth.
Customer Concentration and Loss Impacting Growth: Cencora continues to face headwinds from customer losses, including the exit of a large oncology customer due to acquisition by a competitor. This has already impacted revenue comparisons and will remain a drag through much of fiscal 2026.
Given the scale of large distribution contracts, even a single customer loss can materially affect growth rates. This underscores the company’s exposure to consolidation within healthcare providers and highlights the importance of continuously securing long-term strategic partnerships to stabilize revenue streams.
Integration Risks and Limited Near-Term EPS Contribution from Acquisitions: While OneOncology strengthens long-term positioning, management expects the acquisition to be EPS-neutral in the first 12 months, indicating limited immediate earnings accretion.
The integration of MSO platforms involves operational complexity, including aligning physician networks, systems and services. Any execution missteps could delay synergy realization or increase costs. The reliance on acquisitions to drive growth also introduces execution risk, particularly as the company scales its MSO footprint across multiple specialties and geographies.
Estimate Trend
COR has been witnessing a negative estimate revision trend for fiscal 2026. In the past 30 days, the Zacks Consensus Estimate for earnings has decreased 1 cent to $17.59 per share.
The consensus mark for second-quarter fiscal 2026 revenues is pegged at $80.71 billion, indicating a 7% improvement from the year-ago reported actuals. The bottom-line estimate is pinned at $4.81, implying year-over-year growth of 8.8%.
Stocks to Consider
Some better-ranked stocks in the broader medical space are Intuitive Surgical ISRG, Align Technology ALGN and Cardinal Health CAH.
Intuitive Surgical, sporting a Zacks Rank #2 (Buy) at present, has an estimated long-term growth rate of 15.7%. ISRG’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 13.24%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Intuitive Surgical’s shares have gained 10.9% against the industry’s 6.8% decline over the past six months.
Align Technology, carrying a Zacks Rank #2 at present, has an estimated long-term growth rate of 10.1%. ALGN’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 6.16%.
ALGN’s shares have climbed 27.8% compared with the industry’s 16.7% growth over the past six months.
Cardinal Health, carrying a Zacks Rank of 2, has an estimated long-term growth rate of 15%. CAH’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 9.3%.
CAH’s shares have rallied 45% compared with the industry’s 16.7% growth over the past six months.
5 Stocks Set to Double
Each was handpicked by a Zacks expert as the favorite stock to gain +100% or more in the months ahead. They include
Stock #1: A Disruptive Force with Notable Growth and Resilience
Stock #2: Bullish Signs Signaling to Buy the Dip
Stock #3: One of the Most Compelling Investments in the Market
Stock #4: Leader In a Red-Hot Industry Poised for Growth
Stock #5: Modern Omni-Channel Platform Coiled to Spring
Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor. While not all picks can be winners, previous recommendations have soared +171%, +209% and +232%.
See Our Newest 5 Stocks Set to Double Picks >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report
Align Technology, Inc. (ALGN): Free Stock Analysis Report
Cardinal Health, Inc. (CAH): Free Stock Analysis Report
Cencora, Inc. (COR): Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
Comentarios
Aún no hay comentarios